Literature DB >> 16087772

Anti-GAD antibodies and periodic alternating nystagmus.

Caroline Tilikete1, Alain Vighetto, Paul Trouillas, Jérome Honnorat.   

Abstract

BACKGROUND: Autoantibodies directed against glutamic acid decarboxylase (GAD-Ab) have recently been described in a few patients with progressive cerebellar ataxia, suggesting an autoimmune physiopathologic mechanism.
OBJECTIVE: To determine the exact role of GAD-Ab and gamma-aminobutyric acid (GABA)-ergic neurotransmission in the pathogenesis of cerebellar ataxia.
DESIGN: Case report.
SETTING: University neurological hospital. PATIENT: We report the case of a patient with subacute cerebellar ataxia associated with GAD-Ab showing periodic alternating nystagmus (PAN). INTERVENTION: Baclofen, a GABAergic medication, was given to the patient. MAIN OUTCOME MEASURES: Eye movement recording of spontaneous nystagmus and postrotatory vestibular responses.
RESULTS: Baclofen was effective in suppressing PAN and improving postrotatory vestibular responses but not for improving cerebellar ataxia.
CONCLUSION: The presence of PAN and the response to baclofen provide a unique opportunity to suggest a direct role of GAD-Ab in cerebellar dysfunction in this patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087772     DOI: 10.1001/archneur.62.8.1300

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

Review 1.  Consensus paper: roles of the cerebellum in motor control--the diversity of ideas on cerebellar involvement in movement.

Authors:  Mario Manto; James M Bower; Adriana Bastos Conforto; José M Delgado-García; Suzete Nascimento Farias da Guarda; Marcus Gerwig; Christophe Habas; Nobuhiro Hagura; Richard B Ivry; Peter Mariën; Marco Molinari; Eiichi Naito; Dennis A Nowak; Nordeyn Oulad Ben Taib; Denis Pelisson; Claudia D Tesche; Caroline Tilikete; Dagmar Timmann
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

2.  Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.

Authors:  S Vulliemoz; G Vanini; A Truffert; C Chizzolini; M Seeck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

3.  Gravity-Independent Upbeat Nystagmus in Syndrome of Anti-GAD Antibodies.

Authors:  Daniel Feldman; Jorge Otero-Millan; Aasef G Shaikh
Journal:  Cerebellum       Date:  2019-04       Impact factor: 3.847

4.  Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.

Authors:  S Vulliemoz; G Vanini; A Truffert; C Chizzolini; M Seeck
Journal:  BMJ Case Rep       Date:  2009-02-02

Review 5.  Localizing forms of nystagmus: symptoms, diagnosis, and treatment.

Authors:  Andrew G Lee; Paul W Brazis
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

Review 6.  Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review.

Authors:  José Fidel Baizabal-Carvallo; Marlene Alonso-Juarez
Journal:  J Neural Transm (Vienna)       Date:  2017-07-08       Impact factor: 3.575

7.  GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.

Authors:  Yasushi Hosoi; Makiko Suzuki-Sakao; Tatsuhiro Terada; Takashi Konishi; Yasuomi Ouchi; Hiroaki Miyajima; Satoshi Kono
Journal:  J Neurol       Date:  2013-10-05       Impact factor: 4.849

8.  Alternating skew deviation in association with anti-glutamic acid decarboxylase antibodies.

Authors:  Asim V Farooq; Ketki Soin; Heather E Moss
Journal:  Neuroophthalmology       Date:  2015-05-13

9.  Basic and translational neuro-ophthalmology of visually guided saccades: disorders of velocity.

Authors:  Sushant Puri; Aasef G Shaikh
Journal:  Expert Rev Ophthalmol       Date:  2017-11-28

10.  Gaze-holding and anti-GAD antibody: prototypic heterogeneous motor dysfunction in immune disease.

Authors:  Wanchat Theeranaew; Fajun Wang; Fatema F Ghasia; George Wilmot; Aasef G Shaikh
Journal:  Cerebellum       Date:  2021-05-11       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.